UAE Prostate Cancer Therapeutics Market By Drug Class (Chemotherapy, Immunotherapy, Targeted Therapy, and Hormonal Therapy), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), By Region, Competition, Forecast and Opportunities, 2020-2030F

Market Overview

UAE Prostate Cancer Therapeutics Market was valued at USD 51.28 Million in 2024 and is expected to reach USD 88.26 Million with a CAGR of 9.43% through 2030. 

The UAE Prostate Cancer Therapeutics Market has witnessed steady growth in recent years, driven by the rising incidence of prostate cancer and the increasing demand for advanced treatment options. Prostate cancer, one of the most common cancers among men, has prompted the UAE healthcare sector to focus on innovative therapeutic approaches. A variety of treatment modalities, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies, are widely used in managing prostate cancer. Moreover, the UAE’s high healthcare standards, with a growing emphasis on oncology, contribute significantly to the market’s expansion.  The United Arab Emirates National Cancer Registry (UAE-NCR) 2021 reported that, from January 1 to December 31, 2021, a total of 5,830 patients were diagnosed with either malignant or in situ cancer. Of these, 5,612 cases (96%) were malignant, while 218 cases (4%) were in situ.

 In recent years, key players in the pharmaceutical and biotechnology industries have increasingly introduced novel therapeutics, expanding the treatment landscape for prostate cancer patients. These advancements aim to address unmet needs in patient care, particularly for those diagnosed with metastatic or advanced prostate cancer. Additionally, collaborations between local healthcare providers and international drug manufacturers have facilitated the availability of innovative treatments in the UAE, aligning with global standards in oncology care.

The UAE government’s support for healthcare innovation, coupled with its focus on improving cancer care facilities, has further fueled the market's growth. According to the UAE National Cancer Registry (UAE-NCR) 2021, there is no official nationwide prostate cancer screening program in the UAE. However, most major hospitals offer prostate cancer screening for men as part of a health package at discounted rates. Additionally, certain insurance companies include free annual prostate cancer screenings for all men over the age of 45 as part of their premium insurance plans. Furthermore, the increasing number of prostate cancer screenings, awareness programs, and the aging population have led to early detection and better treatment outcomes. As prostate cancer awareness improves, the demand for personalized medicine, including genetic testing for precision treatment, is also on the rise. As a result, the UAE Prostate Cancer Therapeutics Market is poised for continued growth, driven by medical advancements, strategic investments, and a rising focus on improving patient outcomes in the fight against prostate cancer.

Key Market Drivers

Rising Incidence of Prostate Cancer

The rising incidence of prostate cancer in the UAE is a crucial factor driving the growth of the prostate cancer therapeutics market. Prostate cancer is among the most common cancers affecting men, and the UAE is witnessing an increasing number of cases. Prostate cancer ranks as the second most prevalent cancer among men worldwide, with approximately 1.4 million new cases reported in 2020, as stated by the World Cancer Research Fund. In the UAE, as in many other nations, the incidence of prostate cancer has been increasing steadily, driven by factors such as an aging population and shifts in lifestyle patterns. Additionally, the cost of prostate cancer surgery in the UAE reflects the growing demand for advanced treatment options. This surge is largely attributed to an aging population and lifestyle changes such as poor diet, lack of physical activity, and high rates of smoking, which contribute to higher cancer risks. The country’s healthcare sector is responding to this growing need by focusing on the early detection and treatment of prostate cancer, thus creating an environment that fosters market growth.

The aging male population in the UAE is also a significant contributor, as the risk of developing prostate cancer increases with age. Early detection through regular screening is becoming more common, which allows for more effective treatment outcomes. With increased awareness around prostate cancer prevention and early detection, there is a heightened demand for various therapeutic treatments, including surgery, radiation, and drug-based therapies. Furthermore, healthcare institutions are investing in advanced diagnostic equipment, such as MRIs and biopsies, which aid in the early identification of prostate cancer, leading to earlier and more effective interventions. As more men are diagnosed at an earlier stage, the demand for specialized treatments, particularly those tailored for advanced and metastatic cases, continues to grow. The rising number of prostate cancer cases not only stimulates the demand for therapeutics but also encourages innovation in the treatment landscape. Companies and research institutions are working towards developing more effective therapies that can manage the disease more efficiently, thus fostering market growth in the UAE. As the disease burden increases, so too does the need for advancements in the therapeutic field, which continues to drive the growth of the prostate cancer therapeutics market in the region.

Government and Healthcare Sector Support

The UAE government’s support for healthcare innovation and its strategic investments in the oncology sector are vital drivers for the growth of the prostate cancer therapeutics market. As part of its Vision 2021 plan, the UAE has placed significant emphasis on improving its healthcare infrastructure, including enhancing cancer care services. With the growing number of prostate cancer cases, the government has recognized the importance of creating a robust healthcare system capable of addressing this public health challenge. One of the key initiatives contributing to the market’s expansion is the National Cancer Control Program, which provides funding for cancer research, including prostate cancer. The UAE government has also been proactive in collaborating with international healthcare organizations and pharmaceutical companies to ensure the availability of advanced therapeutics. On 14 September 2022, Arab Health reaffirmed its role as a central hub for healthcare trade, securing AED 2.8 billion in healthcare-related contracts, as reported by the GRS Explori Exhibitor Survey conducted during the 2022 edition, held in Dubai in January. The exhibition plays a vital role in supporting UAE Government initiatives such as ‘Make it in the Emirates,’ a platform aimed at developing the UAE’s industrial sector and strengthening its contribution to the national economy. This initiative focuses on 11 priority sectors, including pharmaceuticals and medical technology. This collaboration facilitates the introduction of the latest prostate cancer treatment options, including cutting-edge drug therapies, biologics, and immunotherapies, which otherwise may not be available in the region. Such partnerships foster the growth of the prostate cancer therapeutics market by ensuring that the UAE benefits from global innovations.

In addition to research and funding, the UAE’s healthcare regulatory authorities are focused on creating a favorable environment for the introduction of new cancer treatments. In March 2024, it was announced that mandatory health insurance will be expanded in 2025 to cover all workers in the UAE, ensuring affordable premiums and reasonable benefits. Beginning January 1, 2025, all private sector employees and domestic workers in the UAE will be required to have basic health insurance coverage. This policy expansion will also apply to the northern emirates of Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah, and Fujairah, in addition to the already established mandatory health insurance programs in Abu Dhabi and Dubai, which began several years ago. As a result, the market for prostate cancer therapeutics continues to expand as the UAE enhances its capacity to address the growing need for cancer care.

Advancements in Treatment Technologies

Advancements in treatment technologies are significantly transforming the UAE prostate cancer therapeutics market. These innovations, ranging from new drug therapies to improved diagnostic tools and treatment modalities, are enhancing the way prostate cancer is managed and treated in the UAE. One of the key advancements is the introduction of precision medicine, which tailors treatments to the individual characteristics of each patient. This approach improves the effectiveness of therapies by targeting specific genetic mutations or molecular alterations present in the cancer cells, leading to better treatment outcomes with fewer side effects.

Another major trend is the development of new drug classes, such as androgen receptor inhibitors, which have become essential in the treatment of advanced or metastatic prostate cancer. These therapies target the androgen receptors that are responsible for the growth of prostate cancer cells. The availability of such targeted therapies ensures that patients have access to treatments that specifically address the underlying mechanisms driving the disease, improving survival rates and quality of life.

Immunotherapies are also gaining traction in the UAE market as a promising treatment option for prostate cancer. These therapies aim to enhance the body’s immune system to recognize and fight cancer cells. Additionally, hormone therapies that block or lower the level of androgens, such as testosterone, are increasingly being used in combination with other treatments to manage prostate cancer effectively. The UAE healthcare system is embracing these innovations by integrating cutting-edge technologies into cancer care centers. Hospitals and medical institutions are investing in the latest diagnostic tools, such as high-resolution imaging and genetic profiling, to accurately diagnose prostate cancer at earlier stages and better monitor treatment progress. As a result, advancements in treatment technologies are playing a pivotal role in improving patient outcomes and boosting the prostate cancer therapeutics market in the UAE.

Download Free Sample Report

Key Market Challenges

High Cost of Advanced Therapies

One of the primary challenges facing the UAE Prostate Cancer Therapeutics Market is the high cost of advanced cancer therapies. While the UAE has made significant progress in adopting state-of-the-art treatment options, such as immunotherapies, precision medicine, and robotic surgery, these therapies come with substantial financial burdens. For instance, the cost of drugs like targeted therapies and immunotherapy can be prohibitively expensive, especially for patients who need long-term treatment for advanced or metastatic prostate cancer. These costs often result in financial strain for both patients and healthcare institutions.

Healthcare in the UAE is primarily funded through private insurance, which may not cover the full range of advanced cancer treatments, leaving patients to bear a significant portion of the costs. While the government provides some financial assistance for cancer care, it is often insufficient to cover the high costs associated with cutting-edge therapies. Consequently, many patients may have limited access to the most effective treatment options, hindering overall market growth. In addition, the price of cancer drugs is influenced by several factors, including the complexity of production, regulatory approval processes, and research and development investments. The global nature of the pharmaceutical industry, where drug prices are subject to international market forces, further complicates the situation. Additionally, the high cost of specialized equipment and technologies used in advanced therapies, such as robotic surgical systems and imaging tools, adds another layer of financial strain on healthcare providers and patients.

Regulatory Barriers and Delays in Approvals

Regulatory barriers and delays in the approval of new therapies pose a significant challenge to the UAE Prostate Cancer Therapeutics Market. While the UAE has made considerable advancements in its healthcare infrastructure, the regulatory approval process for new cancer treatments remains slow, particularly for novel drug therapies and advanced medical devices. The lengthy approval timelines for innovative therapies can delay their availability in the market, which is a critical issue in the fast-evolving field of cancer treatment. Prostate cancer treatments, especially immunotherapies and targeted therapies, are constantly advancing, with new drugs being developed and tested in clinical trials worldwide. However, the UAE’s regulatory agencies, such as the Emirates Food and Drug Authority (EFDA), may take longer than expected to review and approve these therapies. This delay can prevent patients from gaining access to potentially life-saving treatments in a timely manner. The delay in approval also creates a gap between the global availability of these therapies and their introduction in the UAE market, resulting in an inequitable treatment landscape.

Another issue is that regulatory processes may not always align with the rapid pace of innovation in cancer therapeutics. Many novel therapies, such as biologics and cell-based therapies, require specialized regulatory frameworks to ensure their safety and efficacy. However, the UAE’s current regulatory framework may not be fully equipped to handle the complexities associated with these advanced therapies. As a result, pharmaceutical companies may face difficulties in navigating the regulatory landscape, which could delay the launch of new treatments. To overcome this challenge, the UAE’s regulatory authorities need to streamline approval processes and adopt more flexible frameworks that can accommodate the fast-paced nature of cancer research and treatment development. This would allow patients in the UAE to benefit from cutting-edge therapies sooner, helping to propel the growth of the prostate cancer therapeutics market.

Key Market Trends

Availability of Advanced Oncology Treatment Centers

The availability of advanced oncology treatment centers in the UAE has played a significant role in boosting the prostate cancer therapeutics market. As prostate cancer cases rise, the UAE has invested heavily in establishing state-of-the-art cancer centers that are equipped with the latest diagnostic and therapeutic technologies. These specialized centers offer comprehensive prostate cancer care, including screening, diagnosis, surgery, radiation therapy, and access to cutting-edge drug therapies. By centralizing cancer care in specialized centers, the UAE ensures that patients receive the highest quality of care possible. The growth of these advanced oncology centers has made it easier for patients to access specialized prostate cancer treatment. For example, many centers are now equipped with robotic surgical systems, which enable minimally invasive prostate cancer surgeries that reduce recovery times and improve surgical outcomes. Moreover, advanced radiation therapy technologies, such as proton therapy and intensity-modulated radiation therapy (IMRT), are becoming increasingly available, offering more precise and effective treatment for prostate cancer patients.

These oncology centers also serve as hubs for clinical trials, providing prostate cancer patients with access to the latest therapies still in development. Clinical trials are vital in introducing novel drugs and treatment options, and the UAE’s growing network of research institutions and partnerships with international pharmaceutical companies ensures that the latest therapies are available for patients. This integration of clinical trials into oncology centers facilitates the rapid adoption of innovative therapies, contributing to the overall growth of the prostate cancer therapeutics market in the UAE. As the number of specialized cancer centers continues to grow and adopt the latest technologies, the prostate cancer therapeutics market is expected to see further expansion, ensuring that patients have access to world-class treatment options.

Increasing Adoption of Minimally Invasive Therapies

The increasing adoption of minimally invasive therapies in the UAE is driving the growth of the prostate cancer therapeutics market. Minimally invasive procedures, such as robotic-assisted surgery and laparoscopic prostatectomy, are gaining popularity due to their significant benefits over traditional surgical methods. These techniques involve smaller incisions, reduced blood loss, shorter recovery times, and less postoperative pain, which contribute to a quicker return to normal activities for patients. These advantages are particularly important for prostate cancer patients, as they often prefer less invasive options that result in fewer complications and faster recovery. Robotic-assisted surgery, such as the da Vinci surgical system, has revolutionized prostate cancer treatment in the UAE. The precision offered by robotic systems allows surgeons to remove prostate cancer with greater accuracy, minimizing the risk of damaging surrounding tissues and nerves. This has led to improved outcomes, including better urinary and sexual function post-surgery, which are critical concerns for prostate cancer patients. The ability to perform these surgeries with minimal trauma to the body has made them highly appealing to both patients and healthcare providers.

The UAE's healthcare sector has been quick to embrace these advanced minimally invasive techniques. Major hospitals and cancer centers are investing in the latest robotic surgery systems and training their surgical teams to use these technologies effectively. As a result, there has been a shift toward less invasive treatment methods for prostate cancer, which not only boosts patient satisfaction but also contributes to the overall growth of the prostate cancer therapeutics market. This trend is expected to continue as more patients and healthcare providers recognize the benefits of minimally invasive therapies in improving patient outcomes.

Segmental Insights

Drug Class Insights

Based on the Drug Class, Hormonal therapy is currently the dominating drug class in the UAE Prostate Cancer Therapeutics Market. This dominance is primarily due to the widespread use of androgen deprivation therapy (ADT) in the treatment of prostate cancer, particularly for advanced and metastatic cases. Prostate cancer growth is driven by androgens, such as testosterone, and hormonal therapy works by reducing androgen levels or blocking their effects on cancer cells. This makes hormonal therapy a cornerstone of prostate cancer management, especially in the early stages of disease progression. The UAE healthcare system’s adoption of hormonal therapies, including drugs like LHRH agonists and anti-androgens, is driven by their established efficacy, availability, and affordability. Hormonal therapy is often the first-line treatment for locally advanced prostate cancer and is used in combination with other treatment modalities for more advanced stages. The relatively lower cost of hormonal therapy compared to other advanced treatments like chemotherapy and immunotherapy also makes it a preferred choice in a cost-conscious healthcare environment. Hormonal therapy is commonly used in conjunction with other therapies, such as chemotherapy or targeted therapy, to enhance the overall treatment outcome for patients. As a result, this drug class remains a dominant player in the market, both in terms of patient usage and market revenue.

Download Free Sample Report

Regional Insights

Dubai was the dominant region in the UAE Prostate Cancer Therapeutics Market, driven by its status as a major healthcare hub and the concentration of advanced medical facilities. As the largest and most cosmopolitan city in the UAE, Dubai boasts state-of-the-art hospitals, research institutions, and specialized cancer care centers, all of which contribute to the high demand for prostate cancer therapeutics. The presence of leading private healthcare providers such as the American Hospital Dubai and Mediclinic City Hospital ensures that patients have access to the latest treatment options, including chemotherapy, immunotherapy, and targeted therapies. Dubai's strategic location as a medical tourism destination also attracts international patients seeking advanced cancer care, which further fuels the demand for prostate cancer treatments. The city's well-established healthcare infrastructure, combined with its reputation for offering high-quality care, has positioned it as a key market for pharmaceutical companies targeting the prostate cancer therapeutics segment. The UAE government’s commitment to providing top-tier healthcare services, especially in Dubai, has led to continued investment in cutting-edge medical technologies, including robotic surgery and personalized medicine, enhancing treatment outcomes for prostate cancer patients. As a result, Dubai remains the focal point of prostate cancer care, with its hospitals playing a central role in the distribution of therapeutic products.

Recent Developments

• In September 2022, Arab Health highlighted its status as a hub for healthcare trade and demonstrated its commitment to supporting global businesses and governments. According to a GRS Explori Exhibitor Survey, the 2022 edition of the event, held in Dubai in January, facilitated healthcare industry-related contracts worth AED 2.8 billion.  The exhibition also plays a pivotal role in advancing UAE Government initiatives such as 'Make it in the Emirates,' which aims to develop the nation's industrial sector and strengthen its contribution to the economy by focusing on 11 priority areas, including pharmaceuticals and medical technology.
• On October 8, 2024, in Dubai, UAE, Pfizer introduced the UAE's first and only approved oral treatment for metastatic castration-resistant prostate cancer (mCRPC), following its successful launch in the US.  mCRPC, a prostate cancer variant that spreads beyond the prostate and resists testosterone-lowering therapies, affects 10-20% of prostate cancer patients within 5-7 years of diagnosis. Pfizer’s oncology portfolio integrates three core mechanisms—small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including immune-oncology biologics—to target cancer from multiple fronts. The company remains committed to delivering transformative treatments for prevalent cancers such as breast, genitourinary, hematology-oncology, and thoracic cancers, including lung cancer.

Key Market Players

• Pfizer Gulf FZ-LLC
• Julphar (Gulf Pharmaceutical Industries)
• Roche Pharmaceutical Middle East FZCO
• Niner Pharmaceuticals LLC
• Lifepharma FZE
• Hikma UAE
• Al Hayat Pharmaceuticals
• Modern Pharmaceutical Company LLC
• ADCAN Pharma
• Globalpharma Co. (L.L.C.)

Report Scope:

In this report, the UAE Prostate Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

•           UAE Prostate Cancer Therapeutics Market, By Drug Class:

o   Chemotherapy

o   Immunotherapy

o   Targeted Therapy

o   Hormonal Therapy

•          UAE Prostate Cancer Therapeutics Market, By Distribution Channel:

o   Hospital Pharmacies

o   Drug Stores & Retail Pharmacies

o   Online Pharmacies

•          UAE Prostate Cancer Therapeutics Market, By Region:

o   Abu Dhabi

o   Dubai

o   Sharjah

o   Rest of UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the UAE Prostate Cancer Therapeutics Market.

Available Customizations:

UAE Prostate Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

UAE Prostate Cancer Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]